What about the risk of thrombosis with bioresorbable scaffolds?

EuroIntervention

Volumn 11, Issue , 2015, Pages V181-V184

  Capodanno, Davide ^a   Joner, Michael ^b   Zimarino, Marco ^c  

^a UNIVERSITY OF CATANIA   (Italy)

^b CVPATH INSTITUTE   (United States)

^c UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ARTICLE; BIODEGRADATION; BIORESORBABLE SCAFFOLD; DISEASE PREDISPOSITION; DISEASE REGISTRY; DRUG ELUTING STENT; HUMAN; INCIDENCE; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; RISK ASSESSMENT; RISK FACTOR; STENT THROMBOSIS; THROMBOCYTOSIS; THROMBOGENICITY; BIODEGRADABLE IMPLANT; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DEVICE FAILURE; DEVICES; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; PROCEDURES; STATISTICS AND NUMERICAL DATA; TISSUE SCAFFOLD;

ANTITHROMBOCYTIC AGENT;

ABSORBABLE IMPLANTS; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; EQUIPMENT FAILURE; HUMANS; INCIDENCE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TISSUE SCAFFOLDS;

EID: 84929728658     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV11SVA43     Document Type: Article

References (19)

1. van Werkum JW, Heestermans AA, de Korte FI, Kelder JC, Suttorp MJ, Rensing BJ, Zwart B, Brueren BR, Koolen JJ, Dambrink JH, van't Hof AW, Verheugt FW, ten Berg JM. Longterm clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation. 2009; 119: 828-34.
2. Zimarino M, Ausiello A, Contegiacomo G, Riccardi I, Renda G, Di Iorio C, De Caterina R. Rapid decline of collateral circulation increases susceptibility to myocardial ischemia: the trade-off of successful percutaneous recanalization of chronic total occlusions. J Am Coll Cardiol. 2006; 48: 59-65.
3. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Genereux P, Branzi A, Stone GW. Stent thrombosis with drug-eluting stents: is the paradigm shifting? J Am Coll Cardiol. 2013; 62: 1915-21.
4. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, Colombo A, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T, Munzel T, Tamburino C. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015; 10: 1144-53.
5. Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J, Scalone G, Schulz E, Chan MY, Kocka V, Hurtado J, Gomez-Hospital JA, Münzel T, Lee CH, Cequier A, Valdés M, Widimsky P, Serruys PW, Sabaté M. Absorb Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity Score Matching Comparison: The BVSEXAMINATION Study (Bioresorbable Vascular Scaffold-A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction). JACC Cardiovasc Interv. 2015; 8: 189-97.
6. Ishibashi Y, Nakatani S, Onuma Y. Definite and probable bioresorbable scaffold thrombosis in stable and ACS patients. EuroIntervention. 2014 Sep 22. [Epub ahead of print]
7. Kirtane AJ, Stone GW. How to minimize stent thrombosis. Circulation. 2011; 124: 1283-7.
8. Brown AJ, McCormick LM, Braganza DM, Bennett MR, Hoole SP, West NE. Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation. Catheter Cardiovasc Interv. 2014; 84: 37-45.
9. Gomez-Lara J, Radu M, Brugaletta S, Farooq V, Diletti R, Onuma Y, Windecker S, Thuesen L, McClean D, Koolen J, Whitbourn R, Dudek D, Smits PC, Regar E, Veldhof S, Rapoza R, Ormiston JA, Garcia-Garcia HM, Serruys PW. Serial analysis of the malapposed and uncovered struts of the new generation of everolimus-eluting bioresorbable scaffold with optical coherence tomography. JACC Cardiovasc Interv. 2011; 4: 992-1001.
10. Farooq V, Serruys PW, Heo JH, Gogas BD, Onuma Y, Perkins LE, Diletti R, Radu MD, Raber L, Bourantas CV, Zhang Y, van Remortel E, Pawar R, Rapoza RJ, Powers JC, van Beusekom HM, Garcia-Garcia HM, Virmani R. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice. JACC Cardiovasc Interv. 2013; 6: 523-32.
11. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, Coleman L, Wong GK, Edelman ER. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011; 123: 1400-9.
12. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J, Fleckenstein M, Neumann FJ, Sattelberger U, Schmitt C, Muller M, Dirschinger J, Schömig A. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003; 41: 1283-8.
13. Otsuka F, Pacheco E, Perkins LE, Lane JP, Wang Q, Kamberi M, Frie M, Wang J, Sakakura K, Yahagi K, Ladich E, Rapoza RJ, Kolodgie FD, Virmani R. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobaltchromium XIENCE V stent in a porcine coronary artery model. Circ Cardiovasc Interv. 2014; 7: 330-42.
14. Mangiameli A, Ohno Y, Attizzani GF, Capodanno D, Tamburino C. Neoatherosclerosis as the Cause of Late Failure of a Bioresorbable Vascular Scaffold. JACC Cardiovasc Interv. 2015 Mar 17. [Epub ahead of print]
15. Gargiulo G, Mangiameli A, Granata F, Ohno Y, Chisari A, Capodanno D, Tamburino C, La Manna A. New-onset coronary aneurism and late-acquired incomplete scaffold apposition after full polymer jacket of a chronic total occlusion with bioresorbable scaffolds. JACC Cardiovasc Interv. 2015; 8: e41-3.
16. Armstrong EJ, Yeo KK, Javed U, Mahmud E, Patel M, Shunk KA, MacGregor JS, Low RI, Rogers JH. Angiographic stent thrombosis at coronary bifurcations: short-and long-term prognosis. JACC Cardiovasc Interv. 2012; 5: 57-63.
17. Tamburino C, Latib A, van Geuns RJ, Sabate M, Mehilli J, Gori T, Achenbach S, Pan Alvarez M, Nef H, Lesiak M, Di Mario C, Colombo A, Naber CK, Caramanno G, Capranzano P, Brugaletta S, Geraci S, Araszkiewicz A, Mattesini A, Pyxaras SA, Rzeszutko L, Depukat R, Diletti R, Boone E, Capodanno D, Dudek D. Contemporary practice and technical aspects in coronaryintervention with bioresorbable scaffolds: a European perspective. EuroIntervention. 2015 Jan 21. [Epub ahead of print].
18. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrie D, Iniguez A, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015; 385: 43-54.
19. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371: 2155-66.